Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms.

The Cochrane database of systematic reviews·2022
Same author

Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation).

The Cochrane database of systematic reviews·2018
Same author

De-escalation techniques for psychosis-induced aggression or agitation.

The Cochrane database of systematic reviews·2017
Same author

Risperidone versus placebo for schizophrenia.

The Cochrane database of systematic reviews·2016
Same author

Zuclopenthixol versus placebo for schizophrenia.

The Cochrane database of systematic reviews·2015
Same author

Psychoeducation (brief) for people with serious mental illness.

The Cochrane database of systematic reviews·2015
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: Jun 8, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Levomepromazine for schizophrenia.

Parthipan Sivaraman1, Ranganath D Rattehalli, Mahesh B Jayaram

  • 1Bootham Park Hospital, North Yorkshire and York NHS PCT, York, UK, YS30 7BY.

The Cochrane Database of Systematic Reviews
|October 8, 2010
PubMed
Summary
This summary is machine-generated.

Levomepromazine, an older antipsychotic, showed mixed results in schizophrenia treatment. While effective for some symptoms and side effects compared to chlorpromazine and haloperidol, it was less effective than risperidone and caused hypotension.

Related Experiment Videos

Last Updated: Jun 8, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Trials

Background:

  • Levomepromazine is a typical antipsychotic medication for schizophrenia, though infrequently used in the UK.
  • Its clinical utility and safety profile require further investigation.

Purpose of the Study:

  • To evaluate the efficacy and safety of levomepromazine against placebo or other antipsychotics in schizophrenia and schizophreniform psychoses.

Main Methods:

  • A systematic review of randomized controlled trials (RCTs) was conducted.
  • Data from 4 RCTs involving 192 participants were analyzed.
  • Statistical methods included relative risk (RR) and weighted mean differences (WMD) with confidence intervals (CI).

Main Results:

  • Levomepromazine showed no significant difference in study discontinuation compared to other antipsychotics.
  • It was superior to chlorpromazine in reducing Clinical Global Impression (CGI) severity and Brief Psychiatric Rating Scale (BPRS) scores.
  • Risperidone demonstrated better CGI endpoint scores and BPRS response rates than levomepromazine.
  • Levomepromazine was associated with less tremor and need for antiparkinsonian medication compared to haloperidol.
  • However, it caused more hypotension than risperidone and dizziness was common.

Conclusions:

  • Current data are insufficient to definitively establish levomepromazine's effectiveness in schizophrenia treatment.
  • Larger, high-quality studies comparing levomepromazine with other antipsychotics, including clozapine, are necessary.